Lucid Diagnostics closed a public offering that raised $26.9 million, increasing its cash runway to support commercialization efforts for its EsoGuard test, a DNA methylation assay designed to detect esophageal adenocarcinoma. The company plans to use proceeds for general corporate purposes and working capital. The offering precedes anticipated US Centers for Medicare & Medicaid Services coverage, a critical milestone for commercial adoption.